![]() Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, CA, with product manufacturing remaining in El Segundo, CA. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.” We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” said John Milligan, PhD, Gilead’s president and CEO, in a company press release. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets B-cell maturation antigen expressed in multiple myeloma. 29, 2017 under the Prescription Drug User Fee Act.Ī marketing authorization application has also been filed for axi-cel for treating relapsed/refractory DLBCL, TFL, and PMBCL with the European Medicines Agency, representing the first submission in Europe for a CAR T therapy. Kite’s lead therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by FDA for treating refractory aggressive non-Hodgkin lymphoma (NHL), which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL). Kite has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the type of cancer. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second-step merger at the same price as in the tender offer.Īmong the benefits Gilead will gain is a robust pipeline of cell therapy products. Under the merger agreement, a wholly owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite’s common stock at a price of $180 per share in cash. The transaction was unanimously approved by both the Gilead and Kite boards of directors and is anticipated to close in the fourth quarter of 2017. ![]() 28, 2017, Gilead Sciences announced it has agreed to acquire Kite Pharma (Santa Monica, CA), a cell therapy company, for $180 per share in cash, or approximately $11.9 billion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |